Single Dose Radiotherapy Services Market

The market for single-dose radiotherapy services is segmented on the basis of therapies and geography. The therapy segment is further sub-segmented into proton beam therapy (PBT) and conventional radiation therapy (CRT). Geography comprises North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region. The proton beam therapy segment is expected to grow at a faster rate than the conventional radiation therapy segment owing to its improved efficacy in treating cancerous tumors.

The market for single-dose radiotherapy services is segmented on the basis of treatment modality. The modalities covered in this segment are X-ray therapy, computed tomography scanning, magnetic resonance imaging, and radio frequency radiation therapy. This market is divided into medical centers and other types of institutions such as surgical centers, rehabilitation centers, clinics and hospitals, and so on. Radiotherapy is a cancer treatment that uses high-energy x-rays to kill cancer cells. It is one of the most common treatments used today, and it is also one of the most effective. Despite its widespread use, radiotherapy has some significant drawbacks. One of these is that it requires multiple daily doses over a period of several weeks or months.

The single-dose radiotherapy services market is projected to grow at a CAGR of **% during the forecast period of 2018–2031.

Becton, Dickinson and Company, Shire NPS Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Entera Bio Ltd., Amgen Inc., Ascendis Pharma A/S, F. Hoffmann-La Roche Ltd., ProLynx, Inc., Extended Biosciences, Inc., and BionPharma Inc. are the market leaders in Single Dose Radiotherapy Services.